Saltar al contenido
Merck
Todas las fotos(1)

Documentos

L2777

Sigma-Aldrich

Lisinopril

ACE Inhibitor

Sinónimos:

(S)-Nα-(1-Carboxy-3-phenylpropyl)-Lys-Pro

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Número CE:
Código UNSPSC:
12352204
NACRES:
NA.26

Descripción general

Lisinopril is a nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor. It is used in the treatment of heart failure and hypertension. Lisinopril is an antihypertensive and anticongestive agent, like other members of its family. It is water-soluble and possesses weak chelating properties.

Aplicación

Lisinopril has been used as an angiotensin-converting enzyme (ACE) inhibitor:
  • in combination with spironolactone, to study their effects on cardiac and skeletal muscles in the Duchenne muscular dystrophy (DMD) mice model
  • standard in in vitro ACE inhibitory assay
  • as a negative control in ACE enzymatic assay

Pictogramas

Health hazard

Palabra de señalización

Danger

Frases de peligro

Clasificaciones de peligro

Repr. 1A - STOT RE 2

Órganos de actuación

Kidney

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

Eyeshields, Gloves, type N95 (US)


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

A A Patchett et al.
Nature, 288(5788), 280-283 (1980-11-20)
Much current attention focuses on the renin-angiotensin system in relation to mechanisms controlling blood pressure and renal function. Recent demonstrations (ref. 1, ref. 2 and refs therein) that angiotensin-converting enzyme inhibitors show promising clinical antihypertensive properties have been of particular
M L Ricketts et al.
Clinical science (London, England : 1979), 96(6), 669-675 (1999-05-21)
In the kidney and colon 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) inactivates cortisol to cortisone, thereby protecting the non-selective mineralocorticoid receptor from cortisol. Deficiency of 11beta-HSD2 results in cortisol-mediated sodium retention and hypertension, suggesting that the physiological regulation of 11beta-HSD2 in
Comparative Effects of Low and High Doses of the
Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on
Morbidity and Mortality in Chronic Heart Failure
Milton Packer
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale (2017)
E J Wallis et al.
Clinical pharmacology and therapeutics, 64(4), 439-449 (1998-11-03)
The antihypertensive response to angiotensin-converting enzyme (ACE) inhibitors may be attenuated by a compensatory decrease in atrial natriuretic factor production. If so, inhibition of atrial natriuretic factor breakdown by neutral endopeptidase (NEP) may enhance the antihypertensive effects of ACE inhibition.
V B Sørensen et al.
Clinical science (London, England : 1979), 95(6), 709-717 (1998-12-01)
1. Our objective was to compare the effect of a long-acting calcium antagonist (nisoldipine) compared with an angiotensin-converting enzyme inhibitor (lisinopril) on the non-neurogenic regulation of the microvascular blood flow in hypertensive Type I diabetes patients with diabetic nephropathy.2. We

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico